IL2 and melanoma: Of interest, addition of an anti-CXCR3 antibody after ACT in IL-2 NOG mice bearing the Me275 melanoma tumor, known to express CXCR3 ligands i.e. CXCL9/10/1140, with DMβ-transduced T cells (Fig. 3a) significantly impaired tumor control (Fig. 3e).